Peroxisome proliferator-activated receptor gamma agonists also modulate glucose metabolism and insulin sensitivity, thereby reducing plasma glucose and insulin levels in type 2 diabetes (Schwartz et al, 1998). Here, INS is linked to type 2 diabetes mellitus.